METABOLIC EFFECTS OF COMBINED ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH TYPE 2 DIABETES

METABOLIC EFFECTS OF COMBINED ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH TYPE 2 DIABETES

Show other versions (1)

<p><strong>Aim.</strong> To evaluate antihypertensive effect of a 12-week therapy with fixed combination of enalapril and indapamide on insulin resistance (IR), glucose, lipid and purine metabolism in patients with arterial hypertension (HT) and diabetes mellitus (DM) type 2.</p...

Full description

Bibliographic Details
Main Authors: M. E. Statsenko, M. V. Derevyanchenko
Format: Article
Language:English
Published: Столичная издательская компания 2015-09-01
Series:Рациональная фармакотерапия в кардиологии
Subjects:
артериальная гипертензия
сахарный диабет
инсулинорезистентность
метаболическая нейтральность
комбинированная терапия
Online Access:http://www.rpcardio.ru/jour/article/view/54
_version_ 1797714415199453184
author M. E. Statsenko
M. V. Derevyanchenko
author_facet M. E. Statsenko
M. V. Derevyanchenko
author_sort M. E. Statsenko
collection DOAJ
description <p><strong>Aim.</strong> To evaluate antihypertensive effect of a 12-week therapy with fixed combination of enalapril and indapamide on insulin resistance (IR), glucose, lipid and purine metabolism in patients with arterial hypertension (HT) and diabetes mellitus (DM) type 2.</p><p><strong>Material and methods.</strong> 30 patients with HT stage II-III and DM type 2 aged 40-65 years were included into the study. Antihypertensive therapy with fixed-dose combination of enalapril (10 mg) and indapamide(2.5 mg) was initiated for 12 weeks. The level of office systolic blood pressure (SBP) and diastolic blood pressure (DBP), the concentration of glucose, glycosylated hemoglobin, basal insulin, uric acid, fasting lipid profile in the venous blood and IR were assessed.</p><p><strong>Results.</strong> Target blood pressure values were achieved in all patients. After 12 weeks of treatment, there were significant changes in office SBP (Δ%=-23.6) and DBP (Δ%=-12.9) as compared with the baseline values. Metabolic index, characterizing the degree of insulin resistance, decreased significantly by 22.5% (17.8±1.4 baseline vs 13.8±1.4 after 12 weeks of treatment) and atherogenic index decreased by 18.4% (3.16±0.2 baseline vs 2.58±0.17 after 12 weeks of treatment, p&lt;0.05). There was no deterioration of glucose and purine metabolism during the follow-up.</p><p><strong>Conclusion.</strong> Combined antihypertensive therapy with enalapril and indapamide for 12 weeks significantly lowers SBP and DBP, the degree of IR, does not affect carbohydrate, lipid and purine metabolism in patients with HT and DM type 2, i.e. it’s metabolically neutral.</p>
first_indexed 2024-03-12T07:51:32Z
format Article
id doaj.art-36ebcce142874f12b142b56720a12f53
institution Directory Open Access Journal
issn 1819-6446
2225-3653
language English
last_indexed 2024-03-12T07:51:32Z
publishDate 2015-09-01
publisher Столичная издательская компания
record_format Article
series Рациональная фармакотерапия в кардиологии
spelling doaj.art-36ebcce142874f12b142b56720a12f532023-09-02T20:33:10ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532015-09-01111363910.1234/1819-6446-2015-1-36-3953METABOLIC EFFECTS OF COMBINED ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH TYPE 2 DIABETESM. E. Statsenko0M. V. Derevyanchenko1Волгоградский государственный медицинский университетВолгоградский государственный медицинский университет<p><strong>Aim.</strong> To evaluate antihypertensive effect of a 12-week therapy with fixed combination of enalapril and indapamide on insulin resistance (IR), glucose, lipid and purine metabolism in patients with arterial hypertension (HT) and diabetes mellitus (DM) type 2.</p><p><strong>Material and methods.</strong> 30 patients with HT stage II-III and DM type 2 aged 40-65 years were included into the study. Antihypertensive therapy with fixed-dose combination of enalapril (10 mg) and indapamide(2.5 mg) was initiated for 12 weeks. The level of office systolic blood pressure (SBP) and diastolic blood pressure (DBP), the concentration of glucose, glycosylated hemoglobin, basal insulin, uric acid, fasting lipid profile in the venous blood and IR were assessed.</p><p><strong>Results.</strong> Target blood pressure values were achieved in all patients. After 12 weeks of treatment, there were significant changes in office SBP (Δ%=-23.6) and DBP (Δ%=-12.9) as compared with the baseline values. Metabolic index, characterizing the degree of insulin resistance, decreased significantly by 22.5% (17.8±1.4 baseline vs 13.8±1.4 after 12 weeks of treatment) and atherogenic index decreased by 18.4% (3.16±0.2 baseline vs 2.58±0.17 after 12 weeks of treatment, p&lt;0.05). There was no deterioration of glucose and purine metabolism during the follow-up.</p><p><strong>Conclusion.</strong> Combined antihypertensive therapy with enalapril and indapamide for 12 weeks significantly lowers SBP and DBP, the degree of IR, does not affect carbohydrate, lipid and purine metabolism in patients with HT and DM type 2, i.e. it’s metabolically neutral.</p>http://www.rpcardio.ru/jour/article/view/54артериальная гипертензиясахарный диабетинсулинорезистентностьметаболическая нейтральностькомбинированная терапия
spellingShingle M. E. Statsenko
M. V. Derevyanchenko
METABOLIC EFFECTS OF COMBINED ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH TYPE 2 DIABETES
Рациональная фармакотерапия в кардиологии
артериальная гипертензия
сахарный диабет
инсулинорезистентность
метаболическая нейтральность
комбинированная терапия
title METABOLIC EFFECTS OF COMBINED ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH TYPE 2 DIABETES
title_full METABOLIC EFFECTS OF COMBINED ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH TYPE 2 DIABETES
title_fullStr METABOLIC EFFECTS OF COMBINED ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH TYPE 2 DIABETES
title_full_unstemmed METABOLIC EFFECTS OF COMBINED ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH TYPE 2 DIABETES
title_short METABOLIC EFFECTS OF COMBINED ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH TYPE 2 DIABETES
title_sort metabolic effects of combined antihypertensive therapy in patients with type 2 diabetes
topic артериальная гипертензия
сахарный диабет
инсулинорезистентность
метаболическая нейтральность
комбинированная терапия
url http://www.rpcardio.ru/jour/article/view/54
work_keys_str_mv AT mestatsenko metaboliceffectsofcombinedantihypertensivetherapyinpatientswithtype2diabetes
AT mvderevyanchenko metaboliceffectsofcombinedantihypertensivetherapyinpatientswithtype2diabetes

Similar Items